Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
Biogen on Twitter: "Jean-Paul Kress, MD, joins Biogen today as EVP & President, International & Head, Global Therapeutic Operations https://t.co/bJaIERREZ3 https://t.co/BMu0PTC99l" / Twitter
MorphoSys acquires Constellation Pharma for $1.7B - Boston Business Journal
Sanofi Genzyme exec jumps ship to join Biogen
NYC Startup Syntimmune Names Former Biogen Exec as New CEO | BioSpace
Ad hoc: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer | Morphosys de
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
Jean-Paul Kress - CEO - MorphoSys | LinkedIn
Jean-Paul Kress - Biography
Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Samsung, Biogen version of AbbVie's Humira approved in Europe | Reuters
MS Therapies are Focus of Abarca-Biogen Value-based Reimbursement Contract
Jean-Paul Kress Net Worth (2023) | wallmine
Imraldi, Biogen's Humira Biosimilar, Gains EC Approval - Drug Discovery and Development
What Biogen CFO's Departure Means for Company's M&A Strategy | BioSpace
Kress becomes new CEO of MorphoSys - BioM
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
New CEO at Morphosys - European Biotechnology
Morphosys: Das sind die Ziele von CEO Kress & Co - DER AKTIONÄR
Morphosys: Missmanagement bei Deutschlands einstigem Biotechstar - manager magazin
MorphoSys Upbeat Despite Partner Failures In Alzheimer's And Rheumatoid Arthritis :: Scrip
